NCT03927352UnknownPhase 3
A Phase 3, Randomized, Double-blind Study Evaluating the Efficacy and Safety of SCT630 Compared With Adalimumab in Subjects With Moderate to Severe Plaque Psoriasis
Conditions
Trial Snapshot
- Phase
- Phase 3
- Sponsor
- Sinocelltech Ltd.
- Enrollment
- 330
- Locations
- 1
- Primary Endpoint
- Percent Improvement From Baseline in Psoriasis Area and Severity Index (PASI) at Week 16
Study Overview
Brief Summary
The purpose of this research study is to compare the efficacy and safety of SCT630 and adalimumab (HUMIRA®) in adults with plaque psoriasis.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Double (Participant, Investigator)
Eligibility Criteria
- Ages
- 18 Years to 70 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Men or women ≥ 18 and ≤ 70 years of age at time of screening.
- •History of psoriasis for at least 6 months ,and stable moderate to severe plaque psoriasis within 2 months prior to randomized.
- •Moderate to severe psoriasis defined at screening and baseline by：Body surface area (BSA) affected by plaque psoriasis of 10% or greater, and PASI score of 12 or greater, and static physician's global assessment score of 3 or greater.
- •Negative test for Interferon-gamma-release assay an chest X-ray at time of screening.
- •Subject is a candidate for systemic therapy or phototherapy procedures.
- •Female participants must have a negative pregnancy test; are not planning to become pregnant; and must not be lactating.
- •From the screening period to the end (Six months after the last administration),female participants must agree to employ a highly effective contraceptive measure.
Exclusion Criteria
- •Other forms of psoriasis,skin conditions(eg, eczema) or systemic autoimmune diseases which affected the evaluation of treatment outcomes .
- •Received local anti-psoriasis drugs within 2weeks prior to baseline;
- •Received PUVA ,UVB or non-biologics within 4weeks prior to baseline,including methotrexate,Cyclosporine,tretinoins,traditional Chinese medicine,and so on.
- •Received etanercept or its biosimilars within 4weeks prior to baseline.
- •Received other anti-TNF ,IL-12/23inhibitors or IL-17inhibitors within12months prior to baseline.
- •Be receiving or had received any biologics ≤ five half-lives.
- •Patients who previously used adalimumab or a biosimilar of adalimumab ineffectively or intolerantly.
- •History of tuberculosis, active tuberculosis or latent tuberculosis infection.
- •Suffering from active infection or history of infection :Systemic anti-infective therapy was performed 4 weeks before screening, severe infections with hospitalization or intravenous anti-infective treatment within 8 weeks before screening or recurrent, chronic or other active infections which were assessed by researchers to increase the risk of subjects.
- •Subjects were known to have malignant tumors or a history of malignant tumors (except for skin squamous cell carcinoma in situ, basal cell carcinoma, cervical cancer in situ, or skin squamous cell carcinoma with no evidence of recurrence after thorough treatment, or five years prior to investigational product administration)
- •Moderate to severe congestive heart failure (New York Heart Association Classes III or IV）.
- •Subjects with a significant disease other than psoriasis and/or a significant uncontrolled disease (such as, but not limited to, nervous system, renal, hepatic, endocrine, hematological, autoimmune or gastrointestinal disorders)，and which were assessed by researchers to increase the risk of subjects.
- •Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2.5 times upper limit of normal (ULN) ,Hemoglobin < 90 g/L ,Leukocyte count < 3.5×109/L,Platelets < 100×109/L ,Serum creatinine > 2.5 times upper limit of normal (ULN) at Screening.
- •Received any live vaccines ≤4 weeks prior to investigational product administration,or patients who are expecting to receive any live vaccines during the trial.
- •Subjects had hypersensitivity to test drugs and their excipients, or drugs with the same pharmacological and biological classification as test drugs, and had a history of allergy to active substances or excipients of adalimumab or SCT
- •Positive test for anti-nuclear antibody(ANA) or anti-double-stranded DNA antibody at screening.
- •Subjects were accompanied by active neuropathy, including but not limited to multiple sclerosis, Guillain-Barre syndrome, optic neuritis, transverse myelitis, or neurological symptoms suggesting demyelinating lesions of the central nervous system.
- •Positive test for HIV antibodies, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibodies ,or Treponema pallidum antibody at screening.
- •The results of five tests for hepatitis B virus infection should be further tested for hepatitis B virus DNA, if it is greater than or equal to the upper limit of the reference value of each hospital.
- •Women who are pregnant or nursing.
Outcomes
Primary Outcomes
Percent Improvement From Baseline in Psoriasis Area and Severity Index (PASI) at Week 16
Time Frame: Baseline and Week 16
The PASI measures the average redness (erythema), thickness (induration), and scaliness (each graded on a 0 to 4 scale) of psoriasis lesions, weighted by the area of involvement in the four main body areas (i.e., head and neck, trunk, upper extremities, and lower extremities). PASI scores can range from 0.0 to 72.0, with higher scores indicating greater severity and/or more extensive psoriasis. Percent improvement from baseline was calculated as (value at baseline - value at post-baseline visit) × 100 / (value at baseline).
Secondary Outcomes
- Percent Improvement From Baseline in PASI at Week 4、8、12、24、32、48、50(Baseline and week 4、8、12、24、32、48、50)
- Change From Baseline in the Percentage of Body Surface Area (BSA) Involved With Psoriasis at Week 4、8、12、16、24、32、48、50(Baseline and Week 4、8、12、16、24、32、48、50)
- Change From Baseline of dermatology life quality index (DLQI)at Week 4、8、12、16、24、32、48、50(Baseline and Week 4、8、12、16、24、32、48、50)
- Percentage of Participants With a PASI 90 Response at Week 4、8、12、16、24、32、48、50(Baseline and Week 4、8、12、16、24、32、48、50)
- Percentage of Participants With a PASI 50 Response at Week 4、8、12、16、24、32、48、50(Baseline and Week 4、8、12、16、24、32、48、50)
- Percentage of Participants With a PASI 75 Response at Week 4、8、12、16、24、32、48、50(Baseline and Week 4、8、12、16、24、32、48、50)
- Positive rate of ADA and NAb(Week1、4、16、32、48、50、52)
- Percentage of Participants With a PASI 100 Response at Week 4、8、12、16、24、32、48、50(Baseline and Week 4、8、12、16、24、32、48、50)
- Minimum Concentration of SCT630 and EU-licensed Humira(Week1、4、16、32、48、50)
- Percentage of Participants With a Static Physician's Global Assessment (sPGA) Response at Week 4、8、12、16、24、32、48、50(Week 4、8、12、16、24、32、48、50)
- Number of Participants With Adverse Events(Week2、4、8、12、16、24、32、40、48、52)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 3
A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail PsoriasisNail PsoriasisPlaque PsoriasisNCT02016482AbbVie217
Completed
Phase 3
Safety and Efficacy of Adalimumab in Patients With Active Ankylosing SpondylitisAnkylosing SpondylitisNCT00195819Abbott82
Completed
Phase 3
A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal CarcinomaEsophageal CancerNCT04540211Hoffmann-La Roche461
Completed
Phase 3
Adalimumab Administered in Korean Rheumatoid Arthritis Subjects Treated With MethotrexateRheumatoid ArthritisNCT00235859Abbott128
Completed
Phase 3
Study to Demonstrate Non-Inferior Efficacy and Safety of CinnoRA® Versus Humira® for Treatment of Active RAActive Rheumatoid ArthritisNCT03172325Cinnagen136